The tumor inhibiting effect of a newly developed bifunctional nitrosoureido derivative (GYKI-13324) was studied on human colorectal tumor xenograft lines. Given orally in single or multiple daily doses, GYKI-13324 produced long-term or total regression of adenomatous, but only marginal growth delay of mucinous tumors. GYKI-13324, with slightly lower toxicity than that of BCNU, seems to be a candidate in the clinical management of colorectal tumors.
|Number of pages||6|
|Publication status||Published - Dec 1 1981|
ASJC Scopus subject areas
- Cancer Research